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Through the last decades it has become increasingly evident that disease-states involving
cytokines affect the pharmacokinetics of drugs through regulation of expression and activ-
ity of drug metabolizing enzymes, and more recently also drug transporters. The clinical
implication is however difﬁcult to predict, since these effects are dependent on the degree
of inﬂammation and may be changed when the diseases are treated. This article will give
an overview of the present understanding of the effects of cytokines on cytochrome P450
enzymes and drug transporters, and highlight the importance of considering these issues
in regard to increasing use of the relatively new class of drugs, namely therapeutic proteins.
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INTRODUCTION
Differences in drug response among individuals are a great chal-
lenge in order to optimize drug dosage regimen for a patient. The
reason for this variability is multifactorial and include genetic,
environmental, and disease related factors, which may affect
both pharmacodynamics and pharmacokinetics. Understanding
the factors contributing to inter-individual variability in drug
response is of crucial importance both in the development of
new drugs and in optimization of the use of drugs already on
the market.
Factors contributing to determining the pharmacokinetic pro-
ﬁle of a drug include drug metabolizing enzymes and drug trans-
porting proteins. Themost important drugmetabolizing enzymes
are the phase I enzymes belonging to the cytochrome P450 (CYP)
enzyme familywhichmetabolizemany structurally different xeno-
biotics (drug, chemicals), as well as endobiotics (steroids, fatty
acids, prostaglandins; Gonzalez, 1990). There are several CYP sub-
families, of which CYP1, CYP2, and CYP3 are mainly involved
in drug metabolism, and in humans 50% of the overall elimina-
tion of commonly used drugs is performed by these subfamilies
(Wilkinson, 2005). Liver, the principal organ of drug elimination,
is the organ with the highest abundance of CYP enzymes, while
the small intestinal mucosa has been described to be the most
important extra hepatic site of biotransformation (Lin and Lu,
2001). Inter-individual variability in the expression and activity of
CYP enzymes is recognized as signiﬁcant contributor to variation
in drug response. CYP3A4 is the most prominent CYP enzyme,
mainly because it is highly expressed in organs involved in drug
disposition, such as liver, gastrointestinal tract, and kidney (Shi-
mada et al., 1994; Paine et al., 2006) and because of the broad
substrate speciﬁcity. The expression of this isoenzyme displays
a 30- to 60-fold variability in human liver and intestine biop-
sies (Thummel et al., 1994; Paine et al., 1997). The reason for
inter-individual variability in the expression and activity of CYP
enzymes is multifactorial, but may to some degree be explained by
genetic, environmental, and disease related factors.
Themost studied drug transporter is the transmembrane efﬂux
transporter P-glycoprotein (P-gp), a human ABC-transporter
encoded by the ABCB1 gene (Higgins, 1992). P-gp was discov-
ered in 1976 (Juliano and Ling, 1976) as an important multi-drug
resistance (MDR) mechanism in cancer treatment. It is expressed
and distributed in the luminal surface membrane of the ente-
rocytes in the small intestine, renal proximal tubular cells, the
bile canalicular membrane of hepatocytes, the capillary endothe-
lial cells in the blood–brain barrier (BBB) and in different cell
types involved in the immune response (Thiebaut et al., 1987;
Sugawara et al., 1988; Cordon-Cardo et al., 1989; Klimecki et al.,
1994). Based on its localization, the function of P-gp is sus-
pected to be protection of the cells against various toxicants,
among these therapeutically active drugs. As P-gp is abundant
in the intestinal epithelium, one important function is to restrict
oral bioavailability of drugs, and since the substrate speciﬁcity
of P-gp is to a great deal overlapping with that of CYP3A4, the
general view is that P-gp and CYP3A4 work together in restrict-
ing the intestinal bioavailability of drugs (Benet and Cummins,
2001).
Through the last decade, there has been an increasing awareness
on drug transporters other than P-gp and their role in bioavail-
ability, elimination, and tissue distribution of drugs. These include
other ABC transporters such as multidrug-resistance associated
proteins (MRPs), the SLC transporters [e.g., organic anion trans-
porting polypeptides (OATPs),organic anion transporters (OATs),
and organic cation transporters (OCTs)]. Similar to drug metab-
olizing enzymes, there is also a considerable variability in the
expression and activity of drug transporters. This variability is only
to a minor extent explained by genetic polymorphism and other
causes, such as environmental inﬂuence (e.g., drug interactions)
and disease-state also play a role.
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Immunological response and the release of cytokines is part of
the pathophysiology of various diseases like autoimmune diseases,
infections, brain injuries, and cancer. It has been known for sev-
eral decades that cytokines regulate the expression and activity
of drug metabolizing enzymes and thus, may affect the phar-
macokinetics of drugs. More recently it has become evident that
this applies to drug transporters as well. This article will give an
overview of the present understanding of the effects of cytokines
on CYP enzymes and transporters involved in drug pharmaco-
kinetics, and also point out the importance of considering these
issues in regard to the increasing use of the relatively new class
of drugs, namely therapeutic proteins and their involvement in
drug–drug interactions.
IMMUNOLOGICAL RESPONSE AND CYP METABOLISM
Several clinical studies have reported alterations in drug pharma-
cokinetics in patients with inﬂammations, infectious diseases, and
cancer aswell as in critically ill patients (Aitken et al., 2006;Morgan
et al., 2008; Morgan, 2009). Already in 1978 acute virus infec-
tions in asthmatic children were shown to signiﬁcantly increase
the terminal half-life of theophylline (Chang et al., 1978). Also
during an inﬂuenza B out break asthmatic children developed
a sudden decrease in theophylline clearance and were hospital-
ized with toxicity problems (Kraemer et al., 1982). Already in
1976 it was shown that agents causing inﬂammation and infection
depressed hepatic CYP enzymes in rats (Renton and Mannering,
1976a,b) and thus, the decreased theophylline clearance could be
explained by a down-regulation of the CYP enzyme responsible
for the metabolism of theophylline (CYP1A2). Several viruses,
e.g., Herpes simplex, adenovirus, and HIV, have since then been
identiﬁed to depress CYP metabolism and reduce drug clearance
(Anolik et al., 1982; Forsyth et al., 1982; Lee et al., 1993). Also
acute hepatitis virus A infection has been shown to decrease the
excretion of 7-hydroxycoumarin in children and adults, indicating
a depressed CYP2A6 activity during virus infection (Pasanen et al.,
1997). CYP2D6 and CYP3A4 activities have been reported to be
signiﬁcantly lower in patients with chronic hepatitis C compared
to in healthy volunteers (Becquemont et al., 2002). Interestingly,
HIV patients genotyped as CYP2D6 extensive metabolizers (EM)
expressed a shift toward a poor metabolizer (PM) CYP2D6 phe-
notype which correlated with disease activity (O’Neil et al., 2000).
Also bacterial infections cause impaired drug clearance in humans.
Administration of low doses of bacterial lipopolysaccharide (LPS)
to healthy volunteers has been reported to cause reduced clearance
of theophylline, antipyrine, and hexobarbitone (Shedlofsky et al.,
1994, 1997). In rats CYP-mediated drug metabolism is suppressed
during polymicrobial sepsis, particularly in the late phase (Lee and
Lee, 2005).
Several studies have reported decreased theophylline and
aminopyrine clearance following inﬂuenza virus and bacillus
Calmette–Guerin (BCG) vaccination in healthy volunteers (Ren-
ton et al., 1980; Kramer andMcClain, 1981; Gray et al., 1983). The
effect was shown to be largest in individuals with high theophylline
clearance before vaccination (Meredith et al., 1985), probably
those with high CYP1A2 activity. On the other hand, inﬂuenza
immunization did not signiﬁcantly change CYP3A4 or CYP2E1
activities, as measured by the erythromycin breath test (ERMBT)
and chlorzoxazone clearance (Kim and Wilkinson, 1996; Hayney
et al., 2001). However, an inverse correlation between interferon-γ
(IFN-γ) production and changes in ERMBT has been reported
after administration of inﬂuenza vaccine to healthy volunteers
(Hayney and Muller, 2003). In this respect it is interesting to note
that in vitro studies with hepatocytes cultured with IFN-γ showed
a decreased CYP3A4 expression and activity (Donato et al., 1997).
The observed discrepancies in effect of vaccines might be due
to different purity of vaccines, variable vaccination protocols or
differences in response on the various CYP enzymes.
Additionally altered pharmacokinetics is observed in patients
with inﬂammatory diseases and cancer. The largest effect of
inﬂammatory disease on the pharmacokinetics of drugs has been
reported for patients with rheumatoid arthritis, which showed a
three and fourfold higher systemic exposure of verapamil and sim-
vastatin compared to healthy volunteers (Mayo et al., 2000; Zhang
et al., 2009). Also in patients with advanced cancer, all genotyped
as EM of CYP2C19, a reduction in omeprazole metabolism was
observed, and all patients had a slower metabolic CYP2C19 phe-
notype compared to healthy volunteers (Williams et al., 2000).
Similarly decreasedCYP3A4-dependentCsAmetabolismhas been
reported in bone marrow transplanted patients, and interestingly
an association between high interleukin 6 (IL-6) plasma concen-
trations and increasedCsA concentrationswere found (Chen et al.,
1994). Later, Frye et al. (2002) studied the relationship between
plasma concentrations of IL-6 and tumor necrosis factor alpha
(TNF-α) and CYP enzyme activities in patients with congestive
heart failure. IL-6 and TNF-α concentrations were negatively cor-
related to the activities of CYP1A2 and CYP2C19, investigated by
use of caffeine and mephenytoin as probe substrates. There was
no signiﬁcant relationship between the cytokine level andCYP2D6
and CYP2E1 activities in these patients (Frye et al., 2002). In this
respect it is interesting to note that increased adverse events and
discontinuing treatment of the CYP2C19 substrate imipramine
has been reported in heart failure patients (Glassman et al., 1983).
To summarize, depression of metabolic capacity through CYP
enzymes seems to be a common feature of a variety of diseases
involving an immune response with the release of cytokines.
The different CYP enzymes are to a variable degree affected, and
increases in drug exposure from less than 50 to up to 400% have
been observed. The potential effects of cytokines on the phar-
macokinetics of a large number of drugs accounts for increased
awareness in treating patients with diseases involving an immune
response. Also, there are indications of differential effects, with
larger effects on patients with initially high clearance through the
enzyme in question. Thus, depression of CYP activity is a consid-
erable factor contributing to inter-individual variability in drug
exposure.
IMMUNOLOGICAL RESPONSE AND DRUG TRANSPORT
Similar to the drug metabolizing enzymes, a variety of diseases
have also been shown to inﬂuence on the expression of drug trans-
porters. P-gp is in this area by far themost extensively studied drug
transporter. For example, several studies have shown intestinal P-
gp to be inversely correlated with inﬂammatory disease activity.
In a study by Ufer et al. (2009), P-pg mRNA and protein expres-
sion were decreased in patients with ulcerative colitis compared
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to healthy volunteers and P-gp mRNA was inversely correlated
with disease activity. Also, while expression of breast cancer resis-
tance protein (BCRP) and P-gp in inﬂamed mucosa is reduced in
patients with ulcerative colitis, expression of these transporters is
comparable in unaffected mucosa from ulcerative colitis patients
and healthy volunteers (Gutmann et al., 2008). Accordingly, a
post mortem study of seropositive HIV patients showed that P-gp
in brain microvascular endothelial cells was decreased compared
to HIV-negative controls (Langford et al., 2004). However, this
picture ismore complicated as different parts of the brainwere dif-
ferently affected; i.e., in contrast to the aforementioned decrease of
P-gp in endothelial cells, P-gp immunoreactivity was increased in
astroglial cells in AIDS patients with HIV encephalitis compared
to HIV encephalitis-negative patients and seronegative controls
(Langford et al., 2004).
Many in vitro studies have examined the effect of inﬂammatory
mediators on expression and activity of P-gp in the brain (Bauer
et al., 2005;Miller et al., 2008; Roberts and Goralski, 2008). Several
studies show a difference in effect after short-term versus long-
term exposure to inﬂammatory mediators; whereas P-gp activity
is initially depressed, long-term exposure to inﬂammatory media-
tors seems to upregulate P-gp expression and activity (Hartz et al.,
2006; Bauer et al., 2007). Not surprisingly, the magnitude and
direction of changes in drug transport activity is dependent on
both the speciﬁc cytokine and model examined (as reviewed by
Roberts and Goralski, 2008). This is exempliﬁed by the diverg-
ing results of two separate rat models. Seelbach et al. (2007)
reported that P-gp expression in brain microvessels increased 3 h
after induction of inﬂammatory pain. These resultswere accompa-
nied by in situ brain perfusion studies and antinociceptive studies
that showed decreased brain uptake and decreased analgesia of
morphine, a P-gp substrate (Seelbach et al., 2007). In contrast,
Goralski et al. (2003) showed that LPS-inducedCNS inﬂammation
decreased P-gp expression and activity. In this study radioactive
labeled digoxin was increased both in the brain and liver following
intracranial ventricle administration of LPS in male rats (Goralski
et al., 2003). Accordingly, P-gp mRNA in the brain and mRNA
of both P-gp and OATP1B1 in liver were reduced. The diverging
results of in vitro and animal models call for more in vivo studies
to explore the effect of inﬂammatory disease on drug transport
in patients. So far, altered pharmacokinetics of drugs relative to
disease activity has been observed by Roberts et al. (2009). This
group showed that patients with acute inﬂammatory brain injury
obtained increased levels of the morphine metabolites morphine-
3-glucuoronide and morphine-6-glucuronide with increasing IL-
6, while no linkage between the P-gp substrate morphine and CSF
IL-6 was observed. These data suggests an inhibition or down-
regulation of drug efﬂux transporters speciﬁc to these metabolites
other than P-gp in the BBB, possibly OATPs, as postulated by the
authors (Roberts et al., 2009). Taken together, data on the effect
of inﬂammatory mediators/disease on drug exposure in the brain
are not conclusive and more in vivo studies are needed to explore
this issue.
There is increasing evidence for differential ability of cytokines
to inﬂuence on the regulation of expression and activity of drug
transporters in immune cells compared to other tissue (Liptrott
and Owen, 2011). While most studies suggest a depression or
down-regulation of P-gp upon an inﬂammatory response, a recent
study showed that P-gp expressionon lymphocytes inpatientswith
systemic lupus erythematosus (SLE) correlated positively with dis-
ease activity (Tsujimura and Tanaka, 2011). Up-regulation of P-gp
in peripheral blood mononuclear cells has previously been shown
for a variety of diseases, by far most studied in malignant dis-
eases, where it causes the problem of MDR (Kantharidis et al.,
2000; Shtil, 2002), but also in rheumatoid arthritis (Suzuki et al.,
2010), HIV (Langford et al., 2004), and in solid organ transplan-
tation (Donnenberg et al., 2001). This observation is supported
by in vitro studies where P-gp in lymphocytes is induced by var-
ious stimuli such as IL-2 (Tsujimura et al., 2004; Liptrott et al.,
2009). Up-regulation of P-gp and other drug transporters result-
ing is a problem in the use of drugs which are P-gp substrates
and have their site of action within the immune cells, where an
up-regulation of P-gp leads to reduced levels of drugs at their
site of action. This applies to drugs such as antiviral agents used
in HIV, immunosuppressants used in autoimmune diseases and
solid organ transplantation, among others.
In vitro studies in human hepatocytes also suggest a role for
proinﬂammatory cytokines in the regulation of a wide range of
drug transporters other than P-gp, such as OATPs, MRPs, OATs,
and OCTs (Le Vee et al., 2008, 2011; Vee et al., 2009). However,
in vivo data is lacking, and more studies are needed to explore the
role of immune response in the regulation of drug transporters
and its effect on the pharmacokinetics of drugs.
MECHANISMS OF CYP AND TRANSPORTER REGULATION BY
CYTOKINES
In response to infections and inﬂammatory diseases, cytokines like
interferons (IFNs), interleukins (IL-1 and IL-6), and TNFα are
produced and released from monocytes, macrophages, and stro-
mal cells. The mechanisms by which they affect drug metabolism
and transport is not fully understood,but in brief cytokines bind to
receptors on the cell surface in target organs and activate intracel-
lular signal systems regulating gene transcription of enzymes and
transporters. Such receptors include Toll-like receptors (TLRs),
which are presented on the surface of Kupffer cells in the liver
and are involved in mediating inﬂammatory response. In patients
with sepsis, TLR2 and TLR4 expression has been found to be sig-
niﬁcantly up-regulated in several organs (Cinel and Opal, 2009).
It has been shown that CYP enzyme expression was regulated by
a TLR4-dependent mechanism in a LPS-induced inﬂammation
model (Ghose et al., 2008). Several animal studies have shown that
individual CYP enzymes and transporters are down-regulated by
cytokines at the level of gene transcriptionwithdecreases inmRNA
and protein expression (Renton, 2004, 2005; Aitken et al., 2006;
Morgan et al., 2008; Roberts andGoralski, 2008;Miller, 2010). The
major mechanistic explanation involve the transcription factors
pregnane X receptor (PXR) and constitutive androstane receptor
(CAR), which both are involved in the expression of genes asso-
ciated with drug metabolism and transport (Chang andWaxman,
2006).
For CYP3A4 and P-gp transcriptional activation is mediated by
PXR and NF-κB (Bentires-Alj et al., 2003; Gu et al., 2006; Kojima
et al., 2007). Moreover cytokines have been shown to induce
the production of NF-κB, which directly disrupt binding of the
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PXR–retinoid X receptor (RXR) complex to its response element,
leading to suppression of CYP3A4 expression (Gu et al., 2006).
Recently suppression of CYP3A4 by IL-6 was shown to occur after
the decrease of PXR in human hepatocytes (Yang et al., 2010).
Several additional transcription factors may be responsible for
regulation of P-gp expression. Heat-shock transcription factor 1
(HSF-1) and stimulatory protein 1 (SP-1) both have binding sites
within the ABCB1 promoter (Rohlff and Glazer, 1998; Vilaboa
et al., 2000), and in tumor cells P-gp expression is regulated by
Y-box protein (YB-1; Ohga et al., 1998).
Studies in human hepatocytes indicate that the effect of vari-
ous cytokines is gene-speciﬁc.While IL-1down-regulatedCYP2C8
and CYP3A4 mRNA expression by 75 and 95%, respectively, there
was no effect onCYP2C9 orCYP2C19 (Aitken andMorgan, 2007).
IL-6, on the other hand, caused a decrease in CYP2C8, CYP2C9,
CYP2C19, and CYP3A4mRNA expression. Recently IL-6 was also
shown to suppress the activities of CYP3A4 andCYP1A2 in human
primary hepatocytes, while anti-IL-6 monoclonal antibody par-
tially blocked this suppression (Dickmann et al., 2011). The effects
of various cytokines on individual CYP isoenzyme expression and
activity investigated in vitro are summarized in Table 1. With
respect to P-gp, in vitro studies in human hepatoma cells and
human colon carcinoma (Caco-2) cells as well as in vivo studies
in mice have shown that IL-6 and IL-2 down-regulate its expres-
sion (Piquette-Miller et al., 1998; Hartmann et al., 2001; Belliard
et al., 2002; Hosten et al., 2008). On the other hand induction of
P-gp by TNF-α or IL-2 has been shown in mice (Hartmann et al.,
2001), human lymphocytes (Liptrott et al., 2009), and rat brain
capillaries (Bauer et al., 2007). Thus, for P-gp there seems to be
organ- and cytokine-speciﬁc effects. The response of cytokines on
CYP protein expression correlated generally well with the effect on
mRNA expression (Aitken andMorgan, 2007), while P-gp expres-
sion was strongly decreased with no change in mRNA expression
in patients with inﬂammatory gastrointestinal disorders (Blokzijl
et al., 2007).
DRUG INTERACTION WITH THERAPEUTIC PROTEINS
Therapeutic proteins are a group of drugs currently extensively
used in the treatment of autoimmune diseases (e.g., rheumatoid
arthritis), cancer, and HIV. These drugs include monoclonal
antibodies, interferons, and other cytokines among others. Ther-
apeutic proteins are macromolecules, and compared to small-
molecule drugs there is still limited knowledge about their
pharmacokinetics. For small-molecule drugs problems related to
metabolism-based drug–drug interactions have gained extensive
attention as a major cause of adverse drug reactions and toxi-
city problems in general. There are however major differences
regarding clearance mechanisms for small-molecule drugs and
therapeutic proteins. Proteins aremainly cleared by renal ﬁltration
or receptor-mediated clearance, and since they are notmetabolized
by CYP enzymes, drug–drug interactions involving CYP enzymes
have been considered not to be relevant for therapeutic proteins.
However, it has recently been clear that these drugs, due to altering
the immunological state in patients, can affect the pharmacokinet-
ics of a variety of other drugs by interferences with CYP-mediated
metabolism and drug transport (Table 2).
INTERFERONS AND INTERACTIONS WITH CYP METABOLISM
Interferons (IFNs), produced by the immune system in response
to infections and inﬂammations, have antiviral, antiproliferative,
and immunoregulatory effects. INF therapy is extensively used in
the treatment of chronic hepatitis C, multiple sclerosis and can-
cer. In addition to the effect of endogenous cytokines on drug
metabolism, therapeutic use of cytokines may therefore addition-
ally contribute to the decreased metabolic ability. Williams et al.
(1987) reported already in 1987 that 1 day after a single intramus-
cular injection of IFN-α in ﬁve patients with chronic hepatitis B
and four healthy volunteers, clearance of the CYP1A2 substrate
theophylline was signiﬁcantly reduced (30–80%). A 26% reduc-
tion in clearance of theophylline was also observed in patients with
hepatitis C after IFN-β treatment,with a corresponding increase in
terminal half-life of about 40% (Okuno et al., 1993). Additionally
IFN-α administration in patients with hepatitis B has been shown
to cause a minor decrease of erythromycin metabolism (15%), as
determined by ERMBT (Craig et al., 1993), and patients moni-
tored on warfarin needed a dose reduction when IFN-α-2b and
IFN-β were given (Adachi et al., 1995).
Table 1 | Effects of various cytokines on individual drug metabolizing CYP enzyme expression (mRNA or protein) and activity in vitro (no
available data for CYP2D6).
Cytokines CYP enzymes
CYP1A2 CYP2B6 CYP2C8 CYP2C9 CYP2C19 CYP2E1 CYP3A4
IFN-γ ⇓ ⇓ ⇓ ⇓⇔ ⇔ ⇓⇔
TGF-β1 ⇓ ⇑⇓ ⇓ ⇓ ⇓ ⇓
TNF-α ⇓ ⇑⇓ ⇓ ⇓⇔ ⇓⇔ ⇓ ⇓
IL-1β ⇓ ⇓ ⇓ ⇓⇔ ⇔ ⇓ ⇓
IL-2 ⇓ ⇓
IL-4 ⇓ ⇑ ⇑ ⇑⇔
IL-6 ⇓ ⇓ ⇓ ⇓ ⇓ ⇓ ⇓
IL-10 ⇔ ⇑
Two arrows indicate that studies show diverging results (Abdel-Razzak et al., 1993, 1994; Donato et al., 1997; Sunman et al., 2004; Aitken and Morgan, 2007; Liptrott
et al., 2009).
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Table 2 | Examples of drug interactions caused by therapeutic proteins.
Therapeutic protein Affected drug Effect Reference
INTERFERONS
INF-α Theophylline 30–80% reduced clearance Williams et al. (1987)
INF-β Theophylline 26% reduced clearance Okuno et al. (1993)
INF-α Erythromycin 15% decreased CYP3A4 activity Craig et al. (1993)
INF-α-2b, INF-β Warfarin Increased concentration Adachi et al. (1995)
INF-α Cyclophosphamide 60% reduced clearance Hassan et al. (1999)
140% increased t1/2
IFN-α-2b Caffeine 60% decreased CYP1A2 activity Islam et al. (2002)
IFN-α-2b Mephenytoin 40% decreased CYP2C19 activity Islam et al. (2002)
INTERLEUKINS
IL-2 Erythromycin 50% decreased CYP3A4 activity Elkahwaji et al. (1999)
MONOCLONALANTIBODIES
Muromonab-CD3 Cyclosporine Increased concentration Vasquez and Pollak (1997)
Basiliximab Cyclosporine Increased concentration Strehlau et al. (2000)
Basiliximab Tacrolimus 60% increased concentration Sifontis et al. (2002)
Tocilizumab Omeprazole 30% decreased AUC Zhang et al. (2009)
Tocilizumab Simvastatin 60% decreased AUC Zhang et al. (2009)
Tocilizumab Simvastatin 40–60% decreased AUC Schmitt et al. (2011)
In cancer patients with multiple myeloma, administration of
IFN-α before treatment with cyclophosphamide caused about
60% decreased clearance and 140% increased peak concentra-
tion and half-life, accompanied by a decreased concentration of
the CYP3A4 metabolite 4-hydroxycyclophosphamide, compared
to when IFN-αwas administered after cyclophosphamide (Hassan
et al., 1999). Also a study in 17 patients with melanoma showed
that the activities of CYP1A2 and CYP2C19, measured by the
probe drugs caffeine andmephenytoin, were 60 and 40% reduced,
respectively, after treatment with high-dose IFN-α-2b (Islam et al.,
2002).
On the other hand when administered in lower doses to hepati-
tis C patients, IFN has been shown to induce a small, statistically
non-signiﬁcant increase in activity of CYP3A4 and CYP2D6 after
1month of exposure,when administered in combinationwith rib-
avirin as antiviral therapy (Becquemont et al., 2002). It is however
important to note that these patients had signiﬁcantly lower pre-
treatmentCYP3A4 andCYP2D6 activities thanhealthy volunteers.
Recently alsoGupta et al. (2011) demonstrated that weekly admin-
istration of IFN-α-2b to patients with chronic hepatitis C was
associatedwith small increase inCYP2C8/9 andCYP2D6 activities
in some individuals, while there was no effect on CYP3A4 activity
and a limited inhibitory effect on CYP1A2. IFN-β treatment in
patients with multiple sclerosis revealed unaltered CYP2D6 and
CYP2C19 activities (Hellman et al., 2003). Several studies have
been performed with administration of IFN-α-2b and IFN-α-2a
and possible interaction with methadone, which is predominantly
metabolized byCYP3A4.Aminor increase inmethadone exposure
in hepatitis C patients after multiple doses of peginterferon-α-2b
or peginterferon-α-2a have been reported, but the authors con-
clude that this may not be of any clinical relevance (Sulkowski
et al., 2005; Gupta et al., 2007). However several reports indicate
that IFN could cause a clinically relevant interaction when admin-
istered with drugs that are CYP substrates, but there might be
different effect on the individual CYPs. At least IFN given in high
doses for the treatment of cancer seems to decrease the activity of
CYP3A4, CYP1A2, and CYP2C19, and it is important to be aware
of possible interactions with drugs metabolized through these
enzymes. However, a decreased CYP activity due to the disease-
state in chronic hepatitis patients may be restored by antiviral
therapy involving IFN.
INTERLEUKIN AND INTERACTIONS WITH CYP METABOLISM
Interleukins (ILs) are cytokines mainly synthesized by T lym-
phocytes, as well as monocytes, macrophages, and endothelial
cells. They promote the development and differentiation of T,
B, and hematopoietic cells. Therapeutic administration of IL-2
has shown several immunological effects, including activation of
cellular immunity and production of cytokines (Winkelhake and
Gauny, 1990). Recombinant IL-2 is used to treat advanced cancers
(Vlasveld et al., 1992), but there is not much clinical data on the
effect of IL-2 on CYP metabolism. However, high-dose admin-
istration of IL-2 to patients with liver cancer has been shown to
decrease expression of CYP1A2,CYP2C,CYP2E1, and CYP3A4 by
approximately 40–60%, and also the CYP1A2 and CYP3A4 activi-
ties were 62 and 50% reduced, respectively (Elkahwaji et al., 1999).
Thus administration of IL-2 to cancer patients has been proposed
to cause clinically important drug interactions (Lee et al., 2010).
MONOCLONAL ANTIBODIES AND INTERACTIONS WITH CYP
METABOLISM
Human monoclonal antibodies are widely used for treatment of
several diseases, e.g., autoimmune diseases (rheumatoid arthritis),
cancer, and rejection episodes following transplantation. Since
it is now recognized that cytokines induce alterations in CYP
metabolism of drugs, it is also evident that cytokine modulators
may have an effect on CYP-mediated drug metabolism. How-
ever, the prediction of this effect is not straightforward. Use of
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the monoclonal antibody muromonab-CD3 (OKT3), as antilym-
phocyte induction therapy, has been shown to cause a signiﬁcant
increase in cyclosporine A (CsA) trough levels in adult renal
transplant recipients (Vasquez and Pollak, 1997). The mecha-
nism behind this elevated CsA levels is not known, but it has
been hypothesized to be mediated by down-regulation of CYP
enzymes by cytokines, because OKT3 administration has been
reported to cause cytokine release (especially TNF-α and IFN-γ;
Chatenoud et al., 1989). Similarly treatment with the immuno-
suppressive agent basiliximab, a monoclonal antibody against the
IL-2 receptor, in 24 renal transplanted children gave a substantial
increase in the whole-blood CsA concentration compared to 15
recipients who received placebo (Strehlau et al., 2000). Also a 63%
higher tacrolimus concentration was reported in 12 adult renal
transplant recipients 2 days after basiliximab induction therapy
compared to eight patients who received antithymocyte globulin
therapy (Sifontis et al., 2002). The mechanism for this interaction
between basiliximab and CsA or tacrolimus is unclear, but the
authors have suggested that the interaction may be mediated via
cytokine-induced alterations in CYP3A4 metabolism, when basil-
iximab binds to the IL-2 receptor on activated T-cells, circulating
IL-2 may have an effect on intestinal epithelial cells and hepato-
cytes and decrease the expression of CYP3A4 (Elkahwaji et al.,
1999; Strehlau et al., 2000; Sifontis et al., 2002). Additionally, both
tacrolimus and CsA are substrates of P-gp. As P-gp expression is
also regulated by cytokines, the observed effect could be caused by
a combined effect on CYP3A4 and P-gp.
On the other hand it has recently been shown that treat-
ment with certain monoclonal antibodies can restore cytokine-
mediated suppression of hepatic CYP enzymes in inﬂamma-
tory diseases. The consequence might be therapeutic failure by
reduced plasma concentrations of drugs. Tocilizumab, a recom-
binant human monoclonal antibody directed against the IL-6
receptor, inhibits IL-6 binding to both membrane-expressed and
soluble IL-6 receptor (Mihara et al., 2005). Zhang et al. (2009)
reported in 2009 that 1 week following administration of a single
intravenous dose of tocilizumab theAUCs of omeprazole and sim-
vastatin were about 30 and 60% reduced, indicating an increased
activity of CYP2C19 and CYP3A4, respectively. Interestingly the
decrease in plasma concentration of simvastatin persisted for
5weeks. Recently Schmitt et al. (2011) conﬁrmed that tocilizumab
administration reversed the IL-6-induced suppression of CYP3A4
activity in rheumatoid arthritis patients. The AUC of simvas-
tatin was approximately 40 and 60% reduced 1 and 5weeks after
tocilizumab treatment, respectively. As a consequence of these
recent observations, information about the interaction between
tocilizumab and drugs metabolized by CYP enzymes is included
in the summary of product characteristics (SPC) of tocilizumab
(Box 1). This illustrates a disease–drug interaction, where success-
ful treatment of the diseasemay result in risk of therapeutic failure,
due to increased clearance of drugs metabolized by CYP enzymes.
THERAPEUTIC PROTEINS AND INTERACTIONSWITH DRUG TRANSPORT
While there has been an increasing awareness on CYP-mediated
therapeutic protein-small-molecule drug interactions, the possi-
ble effect of therapeutic proteins on drug transporters in humans
is far less studied. However, when drug transporter expression is
Box 1 Cited from the SPC of tocilizumab, in the paragraph
Interaction with other medicinal products and other forms of
interaction (Tocilizumab-SPC)1.
“The expression of hepatic CYP450 enzymes is suppressed
by cytokines, such as IL-6, that stimulate chronic inﬂammation.
Thus, CYP450 expression may be reversed when potent cytokine
inhibitory therapy, such as tocilizumab, is introduced. In vitro
studies with cultured human hepatocytes demonstrated that IL-6
caused a reduction in CYP1A2, CYP2C9, CYP2C19, and CYP3A4
enzyme expression. Tocilizumab normalizes expression of these
enzymes. In a study in RA patients, levels of simvastatin (CYP3A4)
were decreased by 57% 1week following a single dose of
tocilizumab, to the level similar to, or slightly higher than, those
observed in healthy subjects. When starting or stopping therapy
with tocilizumab, patients taking medicinal products which are
individually adjusted and are metabolized via CYP450 3A4, 1A2,
or 2C9 (e.g., atorvastatin, calcium channel blockers, theophylline,
warfarin, phenytoin, ciclosporin A, or benzodiazepines) should be
monitored as doses may need to be increased to maintain ther-
apeutic effect. Given its long elimination half-life (t1/2), the effect
of tocilizumab on CYP450 enzyme activity may persist for several
weeks after stopping therapy.”
altered by infection and inﬂammation, one might presume that
therapeutic inhibition of infectious or inﬂammatory stimuli will
restore transporter levels and activity and subsequently affect drug
disposition. Unfortunately, there is currently not much clinical
data in humans to support this hypothesis and only a very limited
amount of in vitro studies and in vivo studies in animals.
Ben Reguiga et al. (2005) have studies the effect of IFN-α on the
pharmacokinetics of two different P-gp substrates in rats, namely
digoxin and docetaxel. IFN-α given daily for 8 days to rats, was
found to have a dose-dependent inhibitory effect on intestinal P-
gp activity. The pharmacokinetics of oral administered digoxin
showed increased bioavailability while i.v. administered digoxin
was not affected. Since IFN-α is widely used in cancer therapy
and as antiviral therapy, it is combined with anticancer and antivi-
ral drugs, which are P-gp substrates. Increase in bioavailability of
P-gp substrates as well as a potential increase in distribution to
the brain may therefore lead to increased effect and toxicity prob-
lems with these drugs (Goralski et al., 2003). In another study
Ben Reguiga et al. (2007) investigated the effect of IFN-α on the
pharmacokinetics of another P-gp substrate, namely docetaxel, in
rats. They found that the bioavailability of docetaxel was almost
threefold increased as compared to control. Additionally, brain
levels of docetaxel were increased. Also, in mice, a single injec-
tion of IFN-γ resulted in a retardation of plasma elimination
of digoxin and increased tissue levels in liver, kidney, and intes-
tine accompanied by reduced excretion into urine and bile. Slight
down-regulation of P-gp expression and CYP3A4 expression was
also observed (Kawaguchi et al., 2004).
In a recent in vitro study by Chen et al. (2011) OAT2 was
the only drug transporter that was down-regulated under the
inﬂuence of IFN-α2b in human primary hepatocytes, MRP2 was
1http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_
Information/human/000955/WC500054890.pdf.
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signiﬁcantly up-regulated, while a panel of other drug efﬂux and
inﬂux transporters were unaffected. These ﬁndings are in con-
ﬂict with several previous reports, but could be a result of species
differences.
A clinical study on the interaction between etanercept, an
inhibitor of TNF-α, and digoxin concluded on an absence of drug
interaction between these drugs (Zhou et al., 2004a). This con-
clusion could very likely be wrong, as the study was performed in
healthy volunteers with no known inﬂammatory response prior
to administration of etanercept. A similar study and conclusion
has been performed with the CYP2C9 substrate warfarin (Zhou
et al., 2004b). These potentially wrong and harmful conclusions
are referred in the SPC of Enbrel where it is stated that “No clin-
ically signiﬁcant pharmacokinetic drug–drug interactions were
observed in studies with digoxin or warfarin” (Etanercept-SPC)2.
Many important questions on drug interactions between ther-
apeutic proteins and small-molecule drugs remain to be investi-
gated. As pointed out by the FDA, future clinical studies need to be
designed in order to assure a proper investigation of these issues
(Huang et al., 2010).
CLINICAL RELEVANCE OF IMMUNOLOGICAL RESPONSE FOR
PHARMACOKINETICS
It is thus evident that immunological response in different disease-
states as autoimmune diseases, cancer, various infections, and
solid organ transplantation contribute to both intra- and inter-
individual variability in drug pharmacokinetics, and it might be
hypothesized that this underlying mechanismmay lead to adverse
drug reactions in patients. The effect of endogenous cytokines
on drug metabolism may lead to intra-individual variability in
pharmacokinetics due to alterations in the disease-state. Addition-
ally, therapeutic use of cytokines may contribute to the decreased
metabolic ability. On the other hand, relief of a disease related
suppression of drug metabolism by successful treatment may
lead to increased metabolism and therapeutic failure of certain
drugs.
For most drugs the negative correlation between the activity
of inﬂammatory diseases and CYP activities observed in vivo by
use of the cocktail probe approach, indicate a moderate effect
of cytokines, i.e., approximately 50% decreased CYP enzyme
activity, shifting patients to a slower CYP phenotype in var-
ious disease-states. However, there are reports of several-fold
increases in drug exposure due to suppression of drug metab-
olizing enzymes and drug transporters. Also, it must be noted
that even a moderate increase in drug exposure, might for some
drugs and individuals, be of major clinical relevance. This includes
drugs with a narrow therapeutic index and drugs for which
2http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_
Information/human/000262/WC500027361.pdf.
clearance depends entirely on one of the metabolic (e.g., theo-
phylline) or transport (e.g., digoxin) routes being affected by
cytokines, as well as drugs that are substrates of both CYP
enzymes and transporters being regulated by immunological
factors (e.g., cyclosporine A). Also, individuals with genetically
impaired ability to metabolize by certain CYP enzymes or indi-
viduals under treatment with drugs that are strong competitive
or mechanism-based inhibitors of certain CYP enzymes, will be
especially vulnerable to other sources leading to decreased drug
metabolism.
The effect of an immunological response is difﬁcult to pre-
dict, since the effect is dependent on the degree or activity of
the inﬂammation and may be changed with successful treatment
of the disease. It is also important to mention that the mecha-
nism of regulation of drug metabolizing enzymes and drug trans-
porters by immunological response is complex, as there seems to
be cytokine- and organ-speciﬁc effects, which obviously compli-
cates the picture. Nevertheless, both treatment with cytokines and
anti-cytokines may affect the pharmacokinetics of concomitantly
administered drugs (Table 2). While administration of cytokines
such as IFNs and ILs may result in depression of CYP activity and
consequently increased drug exposure, anti-cytokine treatment
may restore the CYP expression and activities, possibly resulting
in therapeutic failure of certain drugs.
Alteration in P-gp activity during inﬂammatory and infec-
tious conditionsmayhave positive or negative clinical implications
depending on the disease and drug affected. The recent ﬁndings
of increased P-gp expression in lymphocytes in autoimmune dis-
eases such as RA and SLE, may be responsible for drug resistance
in these patients. It is therefore possible that these patients might
beneﬁt from concomitantly treatment with P-gp inhibitors, like
tacrolimus or cyclosporine A (Suzuki et al., 2010; Tsujimura and
Tanaka, 2011). The effect of inﬂammatory mediators on P-gp in
the brain is still somewhat unclear. However, a possible decreased
P-gp activity in the BBB may improve the drug efﬁcacy due to
increased concentration within the site of action for treatment of
diseases in the CNS.
CONCLUSION
It is of importance to be aware that disease-states involving
cytokines affect the pharmacokinetics of drugs through regula-
tion of expression and activity of drug metabolizing enzymes and
drug transporters. The clinical implication is however difﬁcult to
predict, since these effects are dependent on the degree of inﬂam-
mation andmay be changedwhen the diseases are treated. It seems
valuable to reconsider the previous impression of drug–drug inter-
actions involving CYP enzymes not being relevant for therapeutic
proteins, as both treatment with cytokines and anti-cytokines may
affect pharmacokinetics of commonly applied drugs, resulting in
altered concentrations in the systemic circulation and also locally
at the various sites of action.
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